Navigation Links
Study reveals risk factors for blood clots in pregnant and postnatal women
Date:4/2/2013

00 pregnancies.

Researchers identified all women who developed VTE for the first time during their pregnancy, including deep vein thrombosis (DVT), then extracted important key information about the mother from their medical records including their age, body mass index (BMI) and whether they smoked.

In addition, they considered other pregnancy-related factors such as how the baby was delivered, whether it was a stillbirth or premature birth and any associated complications including pre-eclampsia, diabetes and high blood pressure.

Co-existing medical factors including varicose veins, inflammatory bowel disease (IBD) and heart conditions such as heart disease were also taken into account.

They then used sophisticated data analysis methods to calculate the incident rate ratios to compare the risks of VTE to people without the specified risk factor.

They discovered that the risk of VTE during pregnancy was only marginally higher for women who were aged over 35 years old, had a BMI greater than 25 or who smoked. Medical complications such as pre-existing diabetes, varicose veins and IBD were all associated with greater risk, but not pre-existing high blood pressure.

The risks were much higher for new mothers. Postnatal women with a BMI greater than 30 were four times more likely to develop a VTE, while delivery by caesarean section, multiple previous births (three or more), bleeding in pregnancy and premature birth all doubled the chances of a women developing a VTE.

Perhaps most significantly, women who suffered a still birth were six times more likely to have a VTE.

Dr Grainge added: "Our results may have important implications for the way that preventative measures for VTE are delivered in healthcare settings in developed countries. We believe the strong association between stillbirths and premature births and VTE in particular is a finding of real importance which has received only limited atten
'/>"/>

Contact: Emma Thorne
emma.thorne@nottingham.ac.uk
44-011-595-15793
University of Nottingham
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. Law that regulates shark fishery is too liberal: UBC study
3. New study will help protect vulnerable birds from impacts of climate change
4. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
5. BYU study: Using a gun in bear encounters doesnt make you safer
6. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
7. Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
8. Crystal structure of archael chromatin clarified in new study
9. EU-funded study underlines importance of Congo Basin for global climate and biodiversity
10. University of Houston study shows BP oil spill hurt marshes, but recovery possible
11. Study demonstrates cells can acquire new functions through transcriptional regulatory network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of ... and other mental capabilities in adults with mild cognitive ... study led by researchers at Wake Forest Baptist Medical ... diagnosed with amnesic mild cognitive impairment (MCI) or mild ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... Ore. In ecosystems around the world, the decline of ... is changing the face of landscapes from the tropics to ... published today in the journal Science shows for ... by humans and loss of prey combine to create global ...
... A team of scientists at LSU Health Sciences Center ... of E6-associated protein (E6AP), an enzyme that acts as a ... time, that the active form of E6AP is composed of ... the ability of nerve cells to "rewire" themselves in response ...
... new technology to squeeze more energy from the fuel release ... power plants do, according to a new analysis accepted for ... of the American Geophysical Union. The so-called "combined cycle" natural ... sulfur dioxide, which can worsen air quality. "Since more ...
Cached Biology News:Loss of large carnivores poses global conservation problem 2Loss of large carnivores poses global conservation problem 3LSUHSC research reveals structure of master regulator and new drug target for autism, cervical cancer 2New study: US power plant emissions down 2
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 7 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX:SDI) today ... the fiscal year ended December 31, 2007., ... its EAA(TM) Endotoxin,Activity Assay, the only FDA ... is a systemic response to bacterial toxins ...
... CLARA, Calif., March 7 Finesse Solutions, LLC, ... sciences process,applications, and Nova Biomedical, Waltham, MA, a ... TruBio(TM) OS plug-in,for OPC connectivity between TruBio(TM) OS ... Basic 2 analyzers. Both companies confirmed that a,TruBio(TM) ...
... SAN DIEGO, March 6 Cadence Pharmaceuticals,Inc. (Nasdaq: ... in-licensing,developing and commercializing proprietary product candidates principally,for use ... will release its,fourth quarter and full year ended ... market on Wednesday, March 12, 2008., Cadence ...
Cached Biology Technology:Spectral announces 2007 financial results 2Spectral announces 2007 financial results 3Spectral announces 2007 financial results 4Spectral announces 2007 financial results 5Spectral announces 2007 financial results 6Spectral announces 2007 financial results 7Spectral announces 2007 financial results 8Spectral announces 2007 financial results 9Finesse Solutions, LLC Announces OPC Connectivity With Nova BioProfile 400 2Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008 2
See product name for description....
Request Info...
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
Panomer 9 oligodeoxynucleotides are random primers that are labeled at the 5' end with our proprietary QSY 7 dye and they are useful for assessing microarray spot morphology, hybridization potential ...
Biology Products: